After 36 months of follow-up, patients were 26% less likely to die or start dialysis, study finds.

SAN DIEGO—Anemia, CKD, and microalbuminuria are each independently associated with an increased risk of all-cause mortality, regardless of the presence of cardiovascular disease (CVD).

Researchers also show that administration of erythropoietin is followed by marked reductions in circulating hepcidin.

Investigators believe elevated levels of endogenous soluble erythropoietin receptors may have a role.

Heart failure and diabetes could make reported risks clinically undetectable.

Ascorbic acid may be effective in managing anemia in hemodialysis (HD) patients, according to a recent meta-analysis by Canadian investigators.

Smaller and more frequent IV iron dosing may result in a significant overall reduction in total iron use, according to a study presented at ASN's Renal Week 2009.

Very large doses of IV iron are associated with decreased long-term survival in patients on hemodialysis, but a new analysis presented at ASN's Renal Week 2009 in San Diego probing this association could not establish a convincing reason for the increased mortality.

Anemia in non-diabetic CKD patients increases their risk of long-term mortality, and this predominantly explained by the association between anemia and degree of renal function, according to a study presented at ASN's Renal Week 2009.

Preemptive replacement of hemodialysis (HD) water treatment components could result in significantly increased hemoglobin levels at lower doses of erythropoiesis-stimulating agents in HD patients, British researchers reported in a study presented at Renal Week 2009.